References
- Chen L, Deng H, Cui H, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9(6):7204–7218.
- Martel-Pelletier J, Lajeunesse D, Reboul P, et al. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2003;62(6):501–509.
- Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta. 2005;1754(1–2):253–262.
- Zheng XY, Chen JC, Xie QM, et al. Anti-inflammatory effect of ciclamilast in an allergic model involving the expression of PDE4B. Mol Med Rep. 2019;19:1728–1738.
- Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015;8:105–118.
- Khan YS, Gutiérrez-de-Terán H, Åqvist J. Molecular mechanisms in the selectivity of nonsteroidal anti-inflammatory drugs. Biochemistry. 2018;57(7):1236–1248.
- Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018;9:1048.
- Bruno F, Spaziano G, Liparulo A, et al. Recent advances in the search for novel 5-lipoxygenase inhibitors for the treatment of asthma. Eur J Med Chem. 2018;153:65–72.
- Tungmunnithum D, Thongboonyou A, Pholboon A, et al. Flavonoids and other phenolic compounds from medicinal plants for pharmaceutical and medical aspects: an overview. Medicines. 2018;5(3):16–93.
- Verma AK, Pratap R. The biological potential of flavones. Nat Prod Rep. 2010;27(11):1571–1593.
- Pérez-Cano FJ, Castell M. Flavonoids, inflammation and immune system. Nutrients. 2016;8(10):659.
- Azam S, Ansari P, Rashid M, et al. In vitro anti-oxidant and in vivo anti-inflammatory activity determination of the methanolic leaves extract of Millettia pachycarpa. Biomed Res Ther. 2015;2:366–373.
- Farzaei MH, Singh AK, Kumar R, et al. Targeting inflammation by flavonoids: novel therapeutic strategy for metabolic disorders. IJMS. 2019;20(19):4957.
- Barik R, Sarkar R, Biswas P, et al. 5,7-Dihydroxy-2-(3-hydroxy-4, 5-dimethoxy-phenyl)-chromen-4-one-a flavone from Bruguiera gymnorrhiza displaying anti-inflammatory properties. Indian J Pharmacol. 2016;48(3):304–311.
- Dzoyem JP, Nkuete AHL, Ngameni B, et al. Anti-inflammatory and anticholinesterase activity of six flavonoids isolated from Polygonum and Dorstenia species. Arch Pharm Res. 2017;40(10):1129–1134.
- Chen L, Teng H, Xie Z, et al. Modifications of dietary flavonoids towards improved bioactivity: an update on structure-activity relationship. Crit Rev Food Sci Nutr. 2018;58(4):513–527.
- Sharma A, Sharma P, Tuli H, et al. Phytochemical and pharmacological properties of flavonols. In: eLS. Chichester: John Wiley & Sons, Ltd.; 2018. p. 1–12.
- Yusof MIM, Salleh MZ, Kek TL, et al. Activity-guided isolation of bioactive constituents with antinociceptive activity from Muntingia calabura L. leaves using the formalin test. Evidence-based complement. Altern. Med. 2013;2013:1–27.
- Serafini M, Peluso I, Raguzzini A. Flavonoids as anti-inflammatory agents. Proc Nutr Soc. 2010;69(3):273–278.
- Gaddipati RS, Raikundalia GK, Mathai ML. Dual and selective lipid inhibitors of cyclooxygenases and lipoxygenase: a molecular docking study. Med Chem Res. 2014;23:1–14.
- Tripuraneni NS, Azam MA. Pharmacophore modeling, 3D-QSAR and docking study of 2-phenylpyrimidine analogues as selective PDE4B inhibitors. J Theor Biol. 2016;394:117–126.
- Cole JC, Nissink JWM, Taylor R. Protein-ligand docking and virtual screening with GOLD. In: Alvarez J, Shoichet B, editors. Virtual screening in drug discovery. 1st ed. Florida: CRC Press; 2005. p. 388–424.
- Jones G, Willett P, Glen RC, et al. Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997;267(3):727–748.
- Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000;28(1):235–242.
- Md Idris MH, Mohd Amin SN, Selvaraj M, et al. High-throughput structure-based drug design of chalcones scaffolds as dual inhibitor of cyclooxygenase-2 and microsomal prostaglandin E synthase-1. J Pharm Sci Emerg Drugs. 2018;6:1–14.
- Shivakumar D, Williams J, Wu Y, et al. Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. J Chem Theory Comput. 2010;6(5):1509–1519.
- Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739–1749.
- Kutil Z, Kvasnicova M, Temml V, et al. Effect of dietary stilbenes on 5-lipoxygenase and cyclooxygenases activities in vitro. Int J Food Prop. 2015;18(7):1471–1477.
- Wisastra R, Kok PA, Eleftheriadis N, et al. Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection. Bioorg Med Chem. 2013;21(24):7763–7778.
- Pufahl RA, Kasten TP, Hills R, et al. Development of a fluorescence-based enzyme assay of human 5-lipoxygenase. Anal Biochem. 2007;364(2):204–212.
- Promega. 2016. PDE-GloTM Phosphodiesterase Assay. https://www.promega.com/-/media/files/resources/protocols/technical-bulletins/101/pde-glo-phosphodiesterase-assay-protocol.pdf.
- Dong J, Wang NN, Yao ZJ, et al. ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. J Cheminform. 2018;10(1):29.
- QikProp. Schrödinger Release 2017-1: QikProp. New York (NY): Schrödinger, LLC; 2017.
- Banerjee P, Eckert AO, Schrey AK, et al. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 2018;46(W1):W257–W263.
- Masunov A. ACD/I-Lab 4.5: an internet service review. J Chem Inf Comput Sci. 2001;41(4):1093–1095.
- Braga RC, Alves VM, Silva MFB, et al. Pred-hERG: a novel web-accessible computational tool for predicting cardiac toxicity. Mol Inform. 2015;34(10):698–701.
- Meerloo J, Van Kaspers GJL, Cloos J. Cell sensitivity assays: the MTT assay. In: Cree IA, editor. Cancer Cell Cult. 2nd ed. London: Humana Press; 2011. p. 237–245.
- Makkar F, Chakraborty K. First report of dual cyclooxygenase-2 and 5-lipoxygenase inhibitory halogen derivatives from the thallus of intertidal seaweed Kappaphycus alvarezii. Med Chem Res. 2018;27(10):2331–2340.
- Xu Z, Yang Z, Liu Y, et al. Halogen bond: its role beyond drug-target binding affinity for drug discovery and development. J Chem Inf Model. 2014;54(1):69–78.
- Hernandes MZ, Cavalcanti SM, Moreira DR, et al. Halogen atoms in the modern medicinal chemistry: hints for the drug design. Curr Drug Targets. 2010;11:1–12.
- Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2004;1(4):337–341.
- Zhang Z, Tang W. Drug metabolism in drug discovery and development. Acta Pharm Sin B. 2018;8(5):721–732.
- Xu Y, Dai Z, Chen F, et al. Deep learning for drug-induced liver injury. J Chem Inf Model. 2015;55(10):2085–2093.
- Kortagere S, Ekins S, Welsh WJ. Halogenated ligands and their interactions with amino acids: implications for structure-activity and structure-toxicity relationships. J Mol Graph Model. 2008;27:70–177.